Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients

In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:New Microbes New Infect
Main Authors: Cadegiani, F.A., Goren, A., Wambier, C.G., McCoy, J.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262389/
https://ncbi.nlm.nih.gov/pubmed/34249367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nmni.2021.100915
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados